Amgen Highlighting Cinacalcet Ability To Meet New Targets In Guidelines
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen’s pre-approval positioning for cinacalcet is focusing on the calcimimetic’s ability to meet the lower target mineral levels set in the National Kidney Foundation’s new guidelines for bone metabolism and disease.
You may also be interested in...
Sensipar Is "Major Breakthrough" For Secondary Hyperparathyroidism – FDA
FDA views Amgen’s Sensipar as a significant therapeutic advance for secondary hyperparathyroidism, NDA review documents state.
Amgen files calcitonin NDA
Amgen submits its first-in-class oral calcimimetic agent, cinacalcet, for the treatment of secondary hyperparathyroidism associated with chronic kidney disease, the firm announces Sept. 8. Cinacalcet modulates the calcium-sensing receptor on the parathyroid gland. The NDA is "based upon the successful completion of Phase III studies"; data will be presented at the American Society of Nephrology annual meeting in November. Cinacalcet is the first small-molecule therapeutic for the biotech firm...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011